Accéder au contenu
Merck

N-linked glycosylation is essential for anti-tumor activities of KIAA1324 in gastric cancer.

Cell death & disease (2023-08-24)
Rebecca Yun, Eunji Hong, Junil Kim, Bora Park, Staci Jakyong Kim, Bona Lee, Yong Sang Song, Seong-Jin Kim, Sujin Park, Jin Muk Kang
RÉSUMÉ

KIAA1324 is a transmembrane protein largely reported as a tumor suppressor and favorable prognosis marker in various cancers, including gastric cancer. In this study, we report the role of N-linked glycosylation in KIAA1324 as a functional post-translational modification (PTM). Loss of N-linked glycosylation eliminated the potential of KIAA1324 to suppress cancer cell proliferation and migration. Furthermore, we demonstrated that KIAA1324 undergoes fucosylation, a modification of the N-glycan mediated by fucosyltransferase, and inhibition of fucosylation also significantly suppressed KIAA1324-induced cell growth inhibition and apoptosis of gastric cancer cells. In addition, KIAA1324-mediated apoptosis and tumor regression were inhibited by the loss of N-linked glycosylation. RNA sequencing (RNAseq) analysis revealed that genes most relevant to the apoptosis and cell cycle arrest pathways were modulated by KIAA1324 with the N-linked glycosylation, and Gene Regulatory Network (GRN) analysis suggested novel targets of KIAA1324 for anti-tumor effects in the transcription level. The N-linked glycosylation blockade decreased protein stability through rapid proteasomal degradation. The non-glycosylated mutant also showed altered localization and lost apoptotic activity that inhibits the interaction between GRP78 and caspase 7. These data demonstrate that N-linked glycosylation of KIAA1324 is essential for the suppressive role of KIAA1324 protein in gastric cancer progression and indicates that KIAA1324 may have anti-tumor effects by targeting cancer-related genes with N-linked glycosylation. In conclusion, our study suggests the PTM of KIAA1324 including N-linked glycosylation and fucosylation is a necessary factor to consider for cancer prognosis and therapy improvement.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Roche
Cocktails d'inhibiteurs de protéases Mini cOmplete, Tablets provided in a glass vial
Sigma-Aldrich
Tunicamycine from Streptomyces sp.
Sigma-Aldrich
Anticorps anti-α-tubuline monoclonal antibody produced in mouse, ascites fluid, clone B-5-1-2
Sigma-Aldrich
SP600125, ≥98% (HPLC)
Sigma-Aldrich
SB 203580, solid, ≥98% (HPLC)
Sigma-Aldrich
Fucosyltransferase Inhibitor, 2F-Peracetyl-Fucose, 2F-Peracetyl-Fucose is a cell-permeable fluorinated fucose derivative that acts as an inhibitor of fucosyltransferases following its uptake and metabolic transformation into a GDP-fucose mimetic.
Sigma-Aldrich
U0126 ethanolate, ≥98% (HPLC), powder
Sigma-Aldrich
Anti-KIAA1324 antibody produced in rabbit, affinity isolated antibody